1.42
Maxcyte Inc stock is traded at $1.42, with a volume of 2.01M.
It is up +0.00% in the last 24 hours and down -36.61% over the past month.
MaxCyte Inc is a commercial cell engineering company focused on providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics and to support cell-based research and development. The company has developed and commercialized a proprietary Flow Electroporation platform, which facilitates the complex engineering of a wide variety of cells. The Company has one reportable segment, cell engineering technology. The revenue is generated from the sale and licensing of company's instruments, as well as sales of single-use disposable processing assemblies.
See More
Previous Close:
$1.42
Open:
$1.43
24h Volume:
2.01M
Relative Volume:
2.23
Market Cap:
$151.38M
Revenue:
$45.44M
Net Income/Loss:
$-35.43M
P/E Ratio:
-4.1765
EPS:
-0.34
Net Cash Flow:
$-25.39M
1W Performance:
+4.41%
1M Performance:
-36.61%
6M Performance:
-63.12%
1Y Performance:
-65.53%
Maxcyte Inc Stock (MXCT) Company Profile
Name
Maxcyte Inc
Sector
Industry
Phone
301-517-5556
Address
9713 KEY WEST AVENUE,, ROCKVILLE
Compare MXCT with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
![]()
MXCT
Maxcyte Inc
|
1.42 | 149.25M | 45.44M | -35.43M | -25.39M | -0.34 |
![]()
ABT
Abbott Laboratories
|
132.59 | 226.73B | 43.11B | 13.94B | 6.78B | 7.98 |
![]()
BSX
Boston Scientific Corp
|
106.17 | 152.69B | 18.49B | 2.50B | 3.49B | 1.68 |
![]()
SYK
Stryker Corp
|
394.22 | 145.89B | 23.82B | 2.92B | 4.02B | 7.55 |
![]()
MDT
Medtronic Plc
|
92.71 | 118.91B | 33.54B | 4.69B | 5.19B | 3.62 |
![]()
EW
Edwards Lifesciences Corp
|
81.83 | 45.97B | 5.69B | 1.41B | 577.90M | 6.95 |
Maxcyte Inc Stock (MXCT) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Aug-11-25 | Downgrade | BTIG Research | Buy → Neutral |
Aug-07-25 | Downgrade | William Blair | Outperform → Mkt Perform |
Jul-22-25 | Initiated | Stephens | Overweight |
Nov-29-23 | Initiated | Craig Hallum | Buy |
Oct-15-21 | Resumed | Cowen | Outperform |
Aug-24-21 | Initiated | BTIG Research | Buy |
Aug-24-21 | Initiated | Cowen | Outperform |
Aug-24-21 | Initiated | Stephens | Overweight |
Aug-24-21 | Initiated | Stifel | Buy |
Aug-24-21 | Initiated | Wedbush | Outperform |
Aug-24-21 | Initiated | William Blair | Outperform |
View All
Maxcyte Inc Stock (MXCT) Latest News
Quant Models Detect Momentum Reversal in MaxCyte Inc.Quarterly Trade Review & High Conviction Trade Alerts - newsyoung.net
MaxCyte Inc. Rebound Backed by Sentiment ShiftPrice Action & Fast Moving Stock Trade Plans - beatles.ru
What makes MaxCyte Inc. stock price move sharplyJuly 2025 Chart Watch & Weekly High Return Forecasts - classian.co.kr
MaxCyte Inc. Testing Reversal Zone on Weekly ChartWeekly Trade Review & Fast Gain Swing Trade Alerts - metal.it
MaxCyte Signs Platform License Agreement With Adicet Bio - Technology Networks
What machine learning models say about MaxCyte Inc.IPO Watch & Reliable Breakout Forecasts - Newser
Why MaxCyte Inc. is moving todayJuly 2025 Catalysts & Free Safe Entry Trade Signal Reports - Newser
What MACD and RSI say about MaxCyte Inc.2025 Biggest Moves & Fast Moving Market Watchlists - Newser
Analyzing the Impact of Earnings Reports on MaxCyte Inc Inc. (MXCT) Price Performance - investchronicle.com
Signal strength of MaxCyte Inc. stock in tech scannersWeekly Trade Analysis & Capital Efficiency Focused Ideas - Newser
Maxcyte Stock Soars 10.87% on Insider Buying - AInvest
Volume spikes in MaxCyte Inc. stock – what they meanIPO Watch & Weekly Top Stock Performers List - Newser
Custom strategy builders for tracking MaxCyte Inc.Treasury Yields & Safe Swing Trade Setup Alerts - Newser
Douglas buys $111k in Maxcyte shares By Investing.com - Investing.com South Africa
Masoud Maher buys Maxcyte (MXCT) shares worth $102,915 - Investing.com
Masoud Maher buys Maxcyte (MXCT) shares worth $102,915 By Investing.com - Investing.com Nigeria
Brooke William buys Maxcyte (MXCT) shares worth $64,500 By Investing.com - Investing.com Canada
Maxcyte CFO Swirsky buys $64.5k in shares By Investing.com - Investing.com Canada
Erck Stanley C, Maxcyte director, buys $137k in MXCT stock - Investing.com Canada
Maxcyte CFO Swirsky buys $64.5k in shares - Investing.com
Brooke William buys Maxcyte (MXCT) shares worth $64,500 - Investing.com India
Maxcyte Director and CFO Make Significant Stock Purchases. - AInvest
Should value investors consider MaxCyte Inc.Game-Changing Investment Alerts - thegnnews.com
Will MaxCyte Inc. continue its uptrendJuly 2025 Trends & Stepwise Trade Signal Implementation - Newser
MaxCyte (NASDAQ:MXCT) Earns Neutral Rating from BTIG Research - Defense World
MaxCyte Inc. Breaks Losing Streak — Is the Trend ReversingFree Premium Stock Market Reports - beatles.ru
Chart based exit strategy for MaxCyte Inc.Oversold Stock Bounce Playbook Generator - Newser
Chartists Watching For Breakout in MaxCyte Inc.Weekly Return Pick Forecast Reports Show Trend - beatles.ru
MaxCyte Chief Commercial Officer Departs Amid Severance Agreement - TipRanks
BTIG Downgrades MaxCyte to Neutral Citing Ongoing Challenges for Cell and Gene Therapy Customers - AInvest
MaxCyte Shares Plummet After Analyst Downgrades and Missed Earnings Estimates - AInvest
MaxCyte Shares Fall After BTIG Downgrade - MarketScreener
MaxCyte Signs Strategic Platform License with Adicet Bio for Cancer and Autoimmune Diseases Treatments. - AInvest
MaxCyte (MXCT) Signed a Strategic Platform License with Adicet Bio - Yahoo Finance
This C3.ai Analyst Turns Bearish; Here Are Top 5 Downgrades For Monday - Benzinga
BTIG Downgrades MaxCyte to Neutral From Buy - MarketScreener
MaxCyte stock rating downgraded to Neutral by BTIG on funding concerns - Investing.com South Africa
MaxCyte signs platform license agreement with Adicet Bio for Gamma Delta T cell therapies - SelectScience
BTIG Downgrades Maxcyte Neutral from Buy Rating - AInvest
MaxCyte signs platform license agreement with Adicet Bio - MSN
Is MaxCyte Inc. Forming a Consolidation BaseMarket Surge Signal for Swing Traders Triggered - beatles.ru
MaxCyte (NASDAQ:MXCT) Lowered to Sell Rating by Wall Street Zen - Defense World
MaxCyte Inc Q2 2025 Earnings: Revenue Falls Short at $8.5 Million, Net Loss Widens to $12.4 Million - AInvest
MaxCyte, Inc. (NASDAQ:MXCT) Q2 2025 Earnings Call Transcript - Insider Monkey
Maxcyte, Inc. shares rise 1.40% after-hours despite William Blair downgrading to Market Perform. - AInvest
MaxCyte, Inc. (MXCT) Reports Q2 Loss, Misses Revenue Estimates - MSN
MaxCyte revises 2025 core revenue guidance to $29.5M-$32.5M amid customer program consolidation - MSN
Maxcyte's 31% Intraday Plunge: Earnings Woes and Sector Turbulence Spark Investor Panic - AInvest
MaxCyte Disappoints With Lower Revenue And Guidance For 2025 - Finimize
William Blair Downgrades MaxCyte to Market Perform From Outperform - MarketScreener
MaxCyte downgraded to Market Perform from Outperform at William Blair - TipRanks
Maxcyte Inc Stock (MXCT) Financials Data
Revenue
Net Income
Cash Flow
EPS
Maxcyte Inc Stock (MXCT) Insider Trading
Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
---|---|---|---|---|---|---|---|
Masoud Maher | President and CEO |
Aug 13 '25 |
Buy |
1.37 |
75,000 |
102,915 |
175,000 |
Erck Stanley C | Director |
Aug 13 '25 |
Buy |
1.37 |
100,000 |
137,220 |
398,328 |
DOUGLAS RICHARD | Director |
Aug 13 '25 |
Buy |
1.39 |
80,000 |
111,040 |
230,577 |
Brooke William W | Director |
Aug 13 '25 |
Buy |
1.29 |
50,000 |
64,500 |
150,879 |
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):